Musayeva Malahat, Sak Serpil Dizbay, Özakıncı Hilal, Boyacıgil Şenay, Coşkun Öznur
Department of Medical Pathology, Ankara University Faculty of Medicine, Ankara, Turkey.
Turk Gogus Kalp Damar Cerrahisi Derg. 2020 Jan 23;28(1):143-150. doi: 10.5606/tgkdc.dergisi.2020.18196. eCollection 2020 Jan.
This study aims to investigate the frequency, distribution, and morphological/immunohistochemical features of epidermal growth factor receptor mutations and to examine the possible relationship between the material type and technical success of mutation analysis in Turkish population with non-small cell lung cancer.
Between September 2012 and December 2015, a total of 499 consecutive, treatment-naïve patients (437 males, 163 females; mean age 61 years; range, 30 to 84 years) with primary or metastatic non-small cell lung cancer who underwent epidermal growth factor receptor mutation testing using Sanger sequencing method were retrospectively analyzed. Archival records and hematoxylin-eosine and immunohistochemically stained sections were re-examined. The thyroid transcription factor-1 and napsin A immunohistochemical stains were performed on tissue array blocks.
Seventy-five mutations were detected in 70 patients (14%). The success rate of testing and intact deoxyribonucleic acid fragment length were significantly higher in the cytological material, compared to tissue specimens (p<0.001). The mutation rate in adenocarcinomas was 33.9% for women and 9.4% for men. The most common mutation was L746-E750del in exon 19 (29.3%), followed by the L858R mutation in exon 21 (28%). The mutation rate was the highest in micropapillary (40%) and lowest in solid (5.4%) adenocarcinomas. All epidermal growth factor receptor mutations, except for one, were positive for the thyroid transcription factor-1. The single nucleotide polymorphism Q787Q in exon 20 was observed in 79.6% of patients.
The frequency and distribution of epidermal growth factor receptor mutations in the Turkish patients with non-small cell lung cancer are similar to the European populations. These results also demonstrate that cytological materials are highly reliable for epidermal growth factor receptor mutation testing, and the probability of detection of wild-type epidermal growth factor receptor is low in cases of thyroid transcription factor-1 negativity.
本研究旨在调查表皮生长因子受体突变的频率、分布及形态学/免疫组化特征,并探讨在土耳其非小细胞肺癌患者中,样本类型与突变分析技术成功率之间的可能关系。
回顾性分析2012年9月至2015年12月期间,共499例采用桑格测序法进行表皮生长因子受体突变检测的初治原发性或转移性非小细胞肺癌患者(437例男性,163例女性;平均年龄61岁;范围30至84岁)。重新检查存档记录以及苏木精-伊红染色和免疫组化染色切片。在组织芯片块上进行甲状腺转录因子-1和 napsin A免疫组化染色。
70例患者(14%)检测到75个突变。与组织样本相比,细胞学样本的检测成功率和完整脱氧核糖核酸片段长度显著更高(p<0.001)。腺癌中女性突变率为33.9%,男性为9.4%。最常见的突变是外显子19中的L746-E750del(29.3%),其次是外显子21中的L858R突变(28%)。微乳头状腺癌的突变率最高(40%),实性腺癌最低(5.4%)。除1例突变外,所有表皮生长因子受体突变的甲状腺转录因子-1均为阳性。外显子20中的单核苷酸多态性Q787Q在79.6%的患者中被观察到。
土耳其非小细胞肺癌患者中表皮生长因子受体突变的频率和分布与欧洲人群相似。这些结果还表明,细胞学样本对于表皮生长因子受体突变检测高度可靠,在甲状腺转录因子-1阴性的病例中检测到野生型表皮生长因子受体的概率较低。